Facebook
Twitter
LinkedIn
ForwardPhysics I and Principles of Clinical Molecular Imaging
Molecular imaging using PET and SPECT is an increasingly used for cancer diagnosis, treatment, and treatment response evaluation. Recent progress in radiopharmaceutical therapy demands effective and quantitative PET and SPECT imaging application for seeing the cancer targets and visualizing what has been treated. In the first presentation, principles of PET and SPECT imaging, challenges and application of quantitation are discussed.
Imaging works as a gatekeeper for theranostics. The second presentation elucidates the significance of target (PSMA, somatostatin receptors) visualization, quantification and heterogeneity in treatment of patients with Lu-177 DOTATATE and Lu-177 PSMA. Methods for response assessments of Lu-177 PSMA and Lu-177 DOTATATE are also briefly discussed.
Topics:
- Physics I – Image Acquisition and Quantitation (PET, SPECT) - Rameshwar Prasad, MS, PhD
- Principles of Clinical Molecular Imaging for Radiopharmaceutical Therapy - Vikas Prasad, MD, PhD
Target Audience
This activity is designed to meet the interests of radiation oncologists, radiation biologists, radiation physicists, radiation dosimetrists, diagnostic radiologists, medical oncologists and radiation oncology residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Explain the role of PET and SPECT in radiopharmaceutical therapy.
- Describe the principles of PET and SPECT imaging.
- Discuss various factors affecting PET and SPECT quantification.
- Differentiate intensity and quality of target (somatostatin receptors, PSMA) expression.
- Discuss new methods for response assessment of radiopharmaceutical therapies.
- Discuss potential values of post-therapy SPECT/CT images in management of patients treated with radiopharmaceuticals.
- Rameshwar Prasad, MS, PhD, is employed by UT Southwestern Medical Center.
- Vikas Prasad, MD, PhD, is employed by Washington University School of Medicine in St. Louis. Dr. Prasad receives honoraria and grant/research funding from Curium and travel expenses from Telix. Dr. Prasad serves as a Pillar Lead with ICPO Academy, is an advisory board member with ENETS and is a faculty member with ESMO.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 2.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.